Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteremia | 31 | 2023 | 155 | 12.740 |
Why?
|
| Anti-Bacterial Agents | 36 | 2023 | 1026 | 8.550 |
Why?
|
| Gram-Negative Bacterial Infections | 16 | 2019 | 62 | 7.000 |
Why?
|
| Drug Resistance, Bacterial | 8 | 2021 | 98 | 2.940 |
Why?
|
| Sepsis | 5 | 2022 | 233 | 2.770 |
Why?
|
| beta-Lactams | 7 | 2019 | 29 | 2.540 |
Why?
|
| Fluoroquinolones | 6 | 2019 | 49 | 2.230 |
Why?
|
| Enterobacteriaceae Infections | 5 | 2019 | 25 | 2.220 |
Why?
|
| Clostridium Infections | 4 | 2021 | 52 | 2.190 |
Why?
|
| Anti-Infective Agents | 6 | 2022 | 166 | 2.100 |
Why?
|
| Community-Acquired Infections | 6 | 2019 | 46 | 2.010 |
Why?
|
| Antimicrobial Stewardship | 6 | 2021 | 33 | 1.970 |
Why?
|
| Cross Infection | 5 | 2021 | 195 | 1.940 |
Why?
|
| Enterobacteriaceae | 5 | 2019 | 29 | 1.580 |
Why?
|
| Escherichia coli Infections | 3 | 2019 | 47 | 1.560 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 156 | 1.480 |
Why?
|
| Retrospective Studies | 26 | 2022 | 7277 | 1.410 |
Why?
|
| Pseudomonas Infections | 3 | 2018 | 83 | 1.410 |
Why?
|
| Gram-Negative Bacteria | 5 | 2021 | 55 | 1.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2021 | 92 | 1.210 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2018 | 133 | 1.170 |
Why?
|
| Aged | 28 | 2020 | 14862 | 1.160 |
Why?
|
| South Carolina | 12 | 2021 | 2752 | 1.150 |
Why?
|
| Urinary Tract Infections | 4 | 2019 | 71 | 1.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 207 | 1.140 |
Why?
|
| Humans | 53 | 2023 | 68618 | 1.000 |
Why?
|
| Escherichia coli | 3 | 2019 | 368 | 0.980 |
Why?
|
| Middle Aged | 30 | 2019 | 21147 | 0.960 |
Why?
|
| Male | 34 | 2020 | 37321 | 0.890 |
Why?
|
| Female | 33 | 2020 | 38074 | 0.860 |
Why?
|
| Aged, 80 and over | 13 | 2019 | 4848 | 0.840 |
Why?
|
| Pandemics | 3 | 2022 | 352 | 0.790 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 56 | 0.790 |
Why?
|
| Drug Utilization Review | 1 | 2021 | 19 | 0.790 |
Why?
|
| Influenza, Human | 1 | 2022 | 79 | 0.780 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 649 | 0.770 |
Why?
|
| Cohort Studies | 10 | 2020 | 2358 | 0.740 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 62 | 0.710 |
Why?
|
| beta-Lactamases | 2 | 2016 | 33 | 0.690 |
Why?
|
| Adult | 20 | 2022 | 21403 | 0.670 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 13 | 0.660 |
Why?
|
| Penicillins | 2 | 2023 | 32 | 0.650 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2019 | 34 | 0.650 |
Why?
|
| Communicable Diseases | 1 | 2019 | 50 | 0.640 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 91 | 0.630 |
Why?
|
| beta-Lactam Resistance | 1 | 2018 | 6 | 0.630 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 504 | 0.630 |
Why?
|
| Pneumonia, Bacterial | 1 | 2018 | 19 | 0.620 |
Why?
|
| Levofloxacin | 2 | 2017 | 23 | 0.610 |
Why?
|
| Carbapenems | 1 | 2017 | 7 | 0.610 |
Why?
|
| Catheter-Related Infections | 2 | 2016 | 43 | 0.610 |
Why?
|
| Bacterial Infections | 1 | 2019 | 163 | 0.600 |
Why?
|
| Drug Hypersensitivity | 1 | 2017 | 35 | 0.600 |
Why?
|
| Hospital Mortality | 2 | 2019 | 384 | 0.590 |
Why?
|
| Risk Factors | 8 | 2022 | 5731 | 0.590 |
Why?
|
| Case-Control Studies | 7 | 2019 | 1553 | 0.590 |
Why?
|
| Pyelonephritis | 1 | 2017 | 17 | 0.580 |
Why?
|
| Cephalosporins | 2 | 2021 | 59 | 0.570 |
Why?
|
| Incidence | 7 | 2019 | 1603 | 0.570 |
Why?
|
| Critical Care | 1 | 2019 | 263 | 0.550 |
Why?
|
| Hospitals | 4 | 2021 | 265 | 0.540 |
Why?
|
| Renal Dialysis | 1 | 2016 | 174 | 0.510 |
Why?
|
| Hospitalization | 2 | 2019 | 978 | 0.500 |
Why?
|
| Inappropriate Prescribing | 1 | 2014 | 27 | 0.480 |
Why?
|
| Area Under Curve | 3 | 2022 | 238 | 0.480 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2020 | 226 | 0.470 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 245 | 0.470 |
Why?
|
| Treatment Outcome | 9 | 2020 | 7029 | 0.470 |
Why?
|
| Prostatic Diseases | 1 | 2013 | 5 | 0.460 |
Why?
|
| Abscess | 1 | 2013 | 37 | 0.450 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 365 | 0.440 |
Why?
|
| Length of Stay | 1 | 2016 | 780 | 0.440 |
Why?
|
| Minnesota | 5 | 2010 | 27 | 0.430 |
Why?
|
| Young Adult | 7 | 2020 | 5717 | 0.430 |
Why?
|
| Prescriptions | 2 | 2020 | 28 | 0.370 |
Why?
|
| Klebsiella Infections | 1 | 2010 | 13 | 0.350 |
Why?
|
| Child | 6 | 2022 | 6405 | 0.330 |
Why?
|
| Infant | 5 | 2019 | 2891 | 0.320 |
Why?
|
| Time Factors | 5 | 2019 | 4655 | 0.320 |
Why?
|
| Graft Survival | 1 | 2011 | 465 | 0.320 |
Why?
|
| Adolescent | 7 | 2020 | 8912 | 0.320 |
Why?
|
| Child, Preschool | 5 | 2019 | 3187 | 0.320 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2279 | 0.310 |
Why?
|
| Prognosis | 4 | 2017 | 2093 | 0.300 |
Why?
|
| Strongyloides stercoralis | 1 | 2007 | 3 | 0.300 |
Why?
|
| Strongyloidiasis | 1 | 2007 | 5 | 0.300 |
Why?
|
| Fungemia | 1 | 2007 | 13 | 0.300 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 33 | 0.300 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 792 | 0.290 |
Why?
|
| Intraabdominal Infections | 2 | 2017 | 19 | 0.290 |
Why?
|
| Administration, Oral | 2 | 2019 | 411 | 0.280 |
Why?
|
| Treatment Failure | 2 | 2017 | 216 | 0.270 |
Why?
|
| Infection Control | 2 | 2019 | 101 | 0.270 |
Why?
|
| Drug Resistance, Microbial | 3 | 2020 | 70 | 0.240 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.240 |
Why?
|
| Seasons | 2 | 2019 | 129 | 0.240 |
Why?
|
| Kidney Transplantation | 2 | 2013 | 839 | 0.240 |
Why?
|
| Global Health | 2 | 2021 | 136 | 0.220 |
Why?
|
| Central Nervous System Infections | 1 | 2023 | 2 | 0.220 |
Why?
|
| Logistic Models | 2 | 2016 | 1420 | 0.210 |
Why?
|
| Vaccination Coverage | 1 | 2022 | 7 | 0.210 |
Why?
|
| Enterococcus | 1 | 2022 | 29 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2016 | 2007 | 0.200 |
Why?
|
| Imipenem | 1 | 2021 | 9 | 0.200 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 5 | 0.200 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2021 | 6 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.190 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1046 | 0.180 |
Why?
|
| Vaccination | 1 | 2022 | 189 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 175 | 0.180 |
Why?
|
| International Cooperation | 2 | 2021 | 88 | 0.180 |
Why?
|
| Serogroup | 1 | 2019 | 6 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 89 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2010 | 274 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 180 | 0.160 |
Why?
|
| Age Distribution | 2 | 2010 | 320 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2017 | 1615 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 109 | 0.160 |
Why?
|
| Phenotype | 1 | 2021 | 947 | 0.150 |
Why?
|
| Propensity Score | 1 | 2018 | 117 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2019 | 206 | 0.150 |
Why?
|
| ROC Curve | 1 | 2019 | 392 | 0.150 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 19 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.150 |
Why?
|
| Disease Progression | 1 | 2020 | 1038 | 0.140 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 21 | 0.140 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2016 | 22 | 0.140 |
Why?
|
| Biological Availability | 1 | 2016 | 79 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2016 | 64 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 931 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 37 | 0.140 |
Why?
|
| Aminoglycosides | 1 | 2016 | 54 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2017 | 714 | 0.130 |
Why?
|
| Southeastern United States | 1 | 2016 | 281 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 567 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2013 | 19 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 55 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2010 | 2455 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2013 | 85 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 364 | 0.110 |
Why?
|
| Kentucky | 2 | 2013 | 13 | 0.100 |
Why?
|
| Recurrence | 2 | 2013 | 948 | 0.100 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 242 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 694 | 0.090 |
Why?
|
| United States | 2 | 2013 | 7367 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 514 | 0.090 |
Why?
|
| Cause of Death | 1 | 2010 | 241 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2010 | 285 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 737 | 0.080 |
Why?
|
| HIV Infections | 1 | 2013 | 791 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 1056 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 3259 | 0.050 |
Why?
|
| Methicillin | 1 | 2023 | 11 | 0.050 |
Why?
|
| Cefazolin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2021 | 7 | 0.050 |
Why?
|
| Politics | 1 | 2021 | 31 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2022 | 97 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 22 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 221 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 326 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 310 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 378 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 581 | 0.030 |
Why?
|
| Tobramycin | 1 | 2016 | 38 | 0.030 |
Why?
|
| Gentamicins | 1 | 2016 | 68 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 703 | 0.030 |
Why?
|
| Critical Illness | 1 | 2016 | 191 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 67 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 700 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 73 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 157 | 0.030 |
Why?
|
| Animals | 1 | 2007 | 20881 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2800 | 0.020 |
Why?
|